logo-loader
viewPolarean Imaging PLC

Polarean has submission for US approval and completion of trials 'clearly in its sights'

Richard Hullihen, CEO of Polarean Imaging PLC (LON:POLX), brings Proactive London's Andrew Scott up to date on developments since their IPO back in March.

The company's recently raised US$4mln to complete their clinical trials and submit an NDA for the FDA.

''We're very happy to now have that clearly in our sights and a straight run through to completion on the trials'', Hullihen says.

Quick facts: Polarean Imaging PLC

Price: 29.625 GBX

AIM:POLX
Market: AIM
Market Cap: £47.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

2 weeks ago

2 min read